Novel LDL receptor analog protein and the gene coding therefor

Abstract: The present invention is drawn to the gene of a novel LDL receptor family receptor which participates in lipoprotein metabolism, a critical factor that triggers the onset of arteriosclerosis. The invention provides DNA having a nucleotide sequence as shown by Sequence ID No. 1 or No.5 is disclosed as well as rabbit tissue or human tissue LDL receptor analog protein having an amino acid sequence of Sequence ID No. 2 or 6 coded by such DNA.

Description: Background of the Invention : 1) Field of the Invention The present invention relates to a novel LDL receptor analog protein having a structure similar to that of LDL receptors that are responsible for the homeostasis mechanism of intracellular cholesterol and extensively participates in serum lipid metabolism, which is a critical factor that triggers the onset of arteriosclerosis. The invention also relates to the gene coding for the protein. 2) Description of the Related Art Abnormality in serum lipid metabolism is one of the most critical risk factors in the onset and progress of arteriosclerosis. Serum lipids, together with apolipoproteins, are transformed into lipoproteins primarily in the liver, secreted therefrom, transported by blood, and taken up by a variety of tissue cells. Uptake of lipoproteins into cells occurs primarily by the mediation of receptors of respective lipoproteins. It is known that low density lipoproteins (LDL), which are taken into cells by specific membrane receptors, called LDL receptors, are metabolized within the cells and utilized as cell membrane components or similar substances. Detailed analysis of familial hyperchlolesterolemia, which is a genetic disease accompanied by notable hyperchlolesterolemia due to abnormality of LDL receptors, has clarified details of the mechanism of homeostasis achieved by LDL receptors with respect to intracellular cholesterol. It has been suggested that living bodies have not only LDL receptors but also cell membrane receptors that recognize other lipoproteins. From analyses of WHHL rabbits, which are model animals lacking LDL receptors, it was found that receptors which takes principally apo-E-containing lipoproteins as ligands (remnant receptors) are present in the liver. It is also predicted that there may be HDL receptors whose ligands are high density lipoprotein (HDL). However, to date, details of the structures and functions of these receptors have not yet been elucidated. It has also been known that foaming of macrophages plays an active role in the formation of atherosclerosis, is deeply participated. Macrophages foam by taking up modified LDL ―not normal LDL― which have undergone oxidation, acetylation, or glycation. There have recently been discovered receptors to modified LDL which are called scavenger receptors. The scavenger receptors have been identified to be membrane receptors that have a structure completely different from that of LDL receptors. Recent research using molecular biological techniques has identified the genes of LRP (LDL receptor-associated protein), gp 330, and VLDL receptors. The receptors have been found to have structures very similar to those of LDL receptors. From analyses of these receptors, it is believed that a plurality of lipoprotein receptors are present in living bodies, and that they are closely related to lipid metabolism. LDL receptors studied in detail by Brown and Goldstein [Brown, M.S. and Goldstein, J.L. (1986) Science 232, 34-47] are known to play an important role in the homeostasis of lipoprotein metabolism in vivo, recognizing apo-B-100 and apo-E and taking primarily LDL as their ligands. Also, LRP, which is a macroprotein, has been found to primarily recognize apo-E and to take β-VLDL or chylomicron remnant as a ligand. Moreover, it has been recently reported that LRP takes an α 2 -macroglobulin/protease complex or a plasminogen activator/plasminogen activator inhibitor-1 complex as a ligand, and that LRP is a protein identical to the α 2 -macroglobulin receptor. When these findings are taken together, LRP is considered to have a wide variety of functions in living bodies [Herz, J., Hamann, U., Rogne, S., Myklebost, O., Gausepohl, H. and Stanley, K.K. (1989) EMBO J. 7(13), 4119-4127; Brown, M.S., - Herz, J., Kowal, R.C. and Goldstein, J.L. (1991) Current Opinion in Lipidology 2, 65-72; Herz, J. (1993) Current Opinion in Lipidology 4, 107-113]. The gp 330, which was first identified as an antigen inducing rat Heymann nephritis, has been reported to have a ligand-binding capacity similar to that possessed by CRP α 2 -macroglobulin receptor [Raychowdhury, R., Niles, J.L., McCluskey, R.T. and Smith, J.A. (1989) Science 244, 1163-1165; Pietromonaco, S., Kerjaschki, D., Binder, S., Ullrich, R. and Farquhar, G. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 1811-1815]. In addition, recently discovered VLDL receptors, which are found to take VLDL as a ligand, are considered to have new functions including fatty acid metabolism, because they are predominantly found in tissues of the heart and muscles though they are rarely found in the liver [Takahashi, S., Kawarabayashi, Y., Nakai, T., Sakai, J. and Yamamoto, T. (1992) Proc. Natl. Acad. Sci. USA 89, 9252-9256]. Functions of these newly found receptors as lipoprotein receptors have been gradually elucidated through detailed in vitro analyses. However, significance of respective receptors in living bodies has mostly been left unknown. In addition, relations to remnant receptors, HDL receptors, etc., which have conventionally been identified or suggested by biochemical techniques, remain unknown. Presently, it is considered that these newly found receptors are products of genes different from those of the latter receptors. Thus, more lipoprotein receptors than originally guessed have become considered to participate in lipoprotein uptake into cells while interacting with each other to thereby function to maintain homeostasis of lipid metabolism in living bodies. However, from structural analyses of the genes of the aforementioned newly-identified receptors, it is predicted that the genes of these receptors that take lipoproteins as ligands are developed from the same gene from which LDL receptors was developed, and thus they are within the same genetic family. This suggests that lipoprotein receptors that have conventionally been proposed may have structures similar to those of LDL receptors. Accordingly, an object of the present invention is to provide the gene of a novel receptor in the LDL receptor family, as well as a protein coded by the gene. The present inventors conducted careful studies so as to attain the above object, and found that by using part of rabbit LDL receptor cDNA as a probe there can be obtained a DNA fragment coding for a peptide having a structure similar to that of LDL receptors. Moreover, when using part of the obtained cDNA as a probe, a cDNA fragment having a sequence similar to that of the cDNA can be obtained from the human tissue cDNA library. The present invention was accomplished based on these findings. Summary of the Invention The present invention provides DNA having a nucleotide sequence shown by Sequence ID No. 1 or No. 5; an LDL receptor analog protein having an amino acid sequence coded by the DNA; a recombinant vector comprising the DNA and a replicable vector; transformant cells which harbor the recombinant vector; and a method for the production of the LDL receptor analog protein. Description of Preferred Embodiment The cDNA of the present invention may be prepared, for example, by the following process. Briefly, the process includes the following steps. (1) Through the use of rabbit LDL receptor cDNA as a probe, positive clones are screened out of a rabbit liver cDNA library. (2) Recombinant DNA is prepared using the separated positive clones, and a cDNA fragment is cut out of the resultant recombinant DNA through a treatment using a restriction enzyme. The cDNA fragment is integrated into a plasmid vector. (3) Host cells are transformed using the obtained cDNA recombinant vector to thereby obtain transformant cells of the present invention. The obtained transformant cells are incubated so as to obtain a recombinant vector containing a DNA fragment of the present invention. The nucleotide sequence of the DNA fragment of the present invention contained in the resultant recombinant vector is determined. (4) In tissue of a living body, there is detected expression of mRNA indicated by the nucleotide sequence of the cDNA of the present invention by using RNA blot hybridization method. (5) Through use of a rabbit cDNA fragment as a probe, positive clones are screened out of a human tissue cDNA library, and the nucleotide sequence of the clones is determined. (6) A recombinant vector for expression is prepared using the cDNA of the present invention. Through use of the thus-obtained vector, host cells are transformed to thereby obtain the transformants of the present invention. (7) Ligands that are bound to protein expressed by the obtained transformants are detected by ligand blotting. Each of the above-described steps will next be described. (1) Screening for positive clones from a rabbit liver cDNA library: A cDNA library may be prepared by the use of mRNA obtained from rabbit liver, reverse transcriptase, and a suitable vector, e.g., commercially available λgt10 vector. A cDNA library thus prepared using λgt10 as a vector is subjected to a screening for positive clones by the application of a DNA hybridization method employing a cDNA probe, to thereby separate positive clones [Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) In: Molecular Cloning: A Laboratory Manual, pp 9.47-9.58, Cold Spring Harbor Laboratory Press].An exemplary cDNA which may be used as a probe is rabbit LDL receptor cDNA. Positive clones may be detected by autoradiography employing a DNA probe labelled with a radioisotope ( 32 P). (2) Preparation of a cDNA recombinant vector: Recombinant vector λgt10 phage DNA is extracted from the isolated positive clones and purified. The resultant purified recombinant vector λgt10 phage DNA is digested with a restriction enzyme EcoRI, to thereby separate a cDNA fragment from the vector DNA. The obtained cDNA fragment is integrated with a plasmid vector for cloning that has been similarly digested with EcoRI, thereby obtaining a recombinant plasmid vector. An exemplary plasmid vector which may be used is pBluescript II. (3) Recombinant vector, transformation of host cells using the recombinant vector, and preparation of DNA: The obtained cDNA recombinant vector is introduced into a variety of host cells that are capable of utilizing the genetic marker possessed by the recombinant vector, to thereby transform the host cells. Host cells are not particularly limited, with E. coli being preferred. For example, a variety of variants of the E. coli K12 strain, e.g., HB-101, may be used. In order to introduce the recombinant vector into host cells, a competent cell method may be used in combination with a treatment with calcium.The thus-obtained transformant cells are cultured in a selective medium in accordance with the genetic marker of the vector. The recombinant vector of the present invention is collected from the cultured cells. The DNA nucleotide sequence of the cDNA contained in the obtained recombinant vector can be determined through use of a dideoxy sequence method [Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. Acd. Sci. USA 74, 5463-5467]. (4) RNA blot hybridization: The expression in tissue of mRNA, indicated by the nucleotide sequence of the cDNA of the present invention, is detected using RNA blot hybridization.First, mRNA is prepared using rabbit tissue. Commercially available oligo(dT)cellulose column may be used for the preparation. In order to prepare mRNA from human tissue, there may be used a commercially available nylon membrane on which tissue poly(A) + RNA from a variety of sources is present.An exemplary probe is the rabbit cDNA obtained in the above-described step (3). mRNA may be detected by autoradiography employing a DNA probe labelled with a radioisotope ( 32 P). (5) Screening of human tissue cDNA library for positive clones, and determination of nucleotide sequence: An exemplary human tissue cDNA library which may be used is a commercially available human brain cDNA library.Screening and nucleotide sequencing of the human brain cDNA library may be performed using a fragment of rabbit cDNA of the present invention as a probe in a manner similar to that used for the aforementioned rabbit liver cDNA library. (6) Preparation of a recombinant vector for expression and transformation of host cells using the recombinant vector for expression: In order to prepare an LDL receptor analog protein through use of cDNA of the present invention, the obtained cDNA and a vector for expression are first bonded to each other to thereby create a recombinant vector for expression. Vectors for expression which may be used for bonding are not particularly limited. For example, pBK-CMV may be used.Host cells are transformed using the thus-obtained recombinant vector for expression, to thereby obtain a transformant cell of the present invention. The obtained transformant cell is cultured so as to obtain cells that are capable of expressing the protein of the invention. Host cells are not particularly limited. For example, CHO cells may be used. In order to introduce the recombinant vector for expression into host cells, a calcium phosphate method may be used.The thus-prepared transformant cells are incubated in a selective medium in accordance with the genetic marker of the vector, so as to express the LDL receptor analog protein of the present invention. (7) Ligand analysis of the protein by ligand blotting: After the resultant transformant cells are incubated, the expressed LDL receptor analog protein is solubilized using a solubilizer, e.g., Triton X-100, to thereby obtain a membrane protein fraction. The fraction is separated using SDS-PAGE, and transferred onto, for example, a nitrocellulose membrane. Using a radio-labelled ( 125 I) lipoprotein as a probe, the analog protein can be detected by autoradiography. Exemplary lipoproteins which may be used include β-VLDL and LDL. Examples: The present invention will next be described in detail by way of example, which should not be construed as limiting the invention. Example 1: Preparation of a rabbit liver cDNA library: From tissue of the liver of a male Japanese white rabbit, intact RNA was extracted through a guanidium thiocyanate/cesium chloride method. The obtained intact RNA was subjected to an oligo (dT) cellulose column method to thereby obtain purified poly(A) + RNA. cDNA was synthesized in accordance with a method of Gubler and Hoffman [Gubler, U. and Hoffman, B.J. (1983) Gene 25, 263]. Briefly, cDNA was synthesized employing rabbit liver poly(A) + RNA (as a template), a random primer, and moloney murine leukemia virus reverse transcriptase. The synthesized cDNA was transformed into double-stranded DNA using DNA polymerase I, and then subjected to an EcoRI methylase treatment. By the use of T4 DNA polymerase, the DNA was blunt-ended. The blunt-ended DNA was ligated to phosphorylated EcoRI linker pd (CCGAATTCGG) using a T4 DNA ligase, and the resultant ligated product was subjected to an additional digestion with EcoRI. cDNA fragments having a size not less than 1 kb were selected by agarose gel electrophoresis, and integrated into the EcoRI-digested site of λgt10 phage DNA using a T4 DNA ligase. The phage DNA was packaged in vitro, to thereby establish a rabbit liver cDNA library. Example 2: Cloning of cDNA of receptors in the rabbit LDL receptor family: The cDNA library (1,000,000 plaques) prepared in Example 1 was subjected to screening using a plaque hybridization method and employing as a probe a segment of the cDNA obtained from a ligand binding region, the functional region, of the rabbit LDL receptor. Hybridization was performed at 42°C using 5 x SSC, 30% formamide, 1% SDS, 5 x Denhardt's, and 100 µg/ml salmon sperm DNA (ssDNA), followed by washing with 0.3 x SSC/0.1% SDS at 48°C. As a result, several positive clones were obtained. These cDNA clones were separated by performing this plaque hybridization method in a plurality of times. Subsequently, a cDNA fragment of each phage was subcloned into a plasmid vector pBluescript II, and the nucleotide sequence was analyzed using a dideoxy sequence method [Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. Acd. Sci. USA 74, 5463-5467]. Based on a putative amino acid sequence, LDL receptors themselves were excluded, and cDNA clones having a sequence very similar to that of LDL receptors were identified. Using these clones as cDNA probes, the cDNA library was screened to thereby obtain overlapping two clones. These were employed as new probes and similar procedure was performed, so as to obtain 5 cDNA clones. The DNA nucleotide sequence determined by these cDNA clones are shown as Sequence ID No. 3. The total length of the sequence was 6961 bp. In the open reading frame of 6639 bp (Sequence ID No. 1) which contained a sequence exhibiting high homology with LDL receptors, there existed on the 5' side an ATG codon which was presumably a translation initiating site and a successive highly hydrophobic sequence consisting of about 30 amino acids. Accordingly, the obtained cDNA was considered to contain the entirety of its length. A putative amino acid sequence is shown as Sequence ID No. 2. The protein consisted of 2213 amino acids. Comparison of the amino acid sequence of the protein with other amino acid sequence data registered at the Genebank, there was a very high similarity to LDL receptors. That is, amino acids 700 - 1,100 in the sequence were very similar to the EGF precursor homology region of LDL receptors, and amino acids 1,100 - 1,640 were also very similar to the ligand binding region of LDL receptors. When the amino acid sequence of the subject protein was compared with other lipoprotein receptor LRP, gp330, and VLDL receptors, similarity was not as high as that observed for LDL receptors. On the C-terminal side of the amino acid sequence of the protein, there was found a highly hydrophobic region which was very similar to the transmembrane region of LDL receptors. Example 3: From liver tissue and brain tissue of a male Japanese white rabbit, intact RNA was extracted through a guanidium thiocyanate/cesium chloride method. The obtained intact RNA was subjected to an oligo (dT) cellulose column method to thereby obtain purified poly(A) + RNA. The poly(A) + RNA specimens (10 µg each) was modified via a glyoxal method, electrophoresed on 1% agarose gel, and transferred onto a nylon membrane. For human tissue mRNA, commercially available nylon membranes blotted with human tissue poly(A) + RNA from various sources were used. Using as a probe part of a 32 P-labelled rabbit cDNA of the present invention, hybridization was performed at 42°C using 50% (rabbit) or 40% (human) formamide, 0.1% SDS, 50 mM phosphate buffer, 5 x Denhardt's, 5 x SSC, and 200 µg/ml of ssDNA, followed by washing with 0.1 x SSC and 0.1% SDS at 50°C. Autoradiography was performed at -70°C for 2 days in the presence of intensifying screen. As a result, in both rabbit liver tissue and brain tissue, mRNA of about 7 kb was detected as well as mRNA of about 15 kb which was considered to result from alternative splicing or polyadenylation. The size of the mRNA of about 7 kb coincided with that of the rabbit cDNA of the present invention. Also, in human liver tissue and brain tissue, it was confirmed that mRNA having the same size was expressed. Example 4: Screening of human brain cDNA library for positive clones and determination of the nucleotide sequence of cDNA fragments The human brain cDNA library used in this Example was a commercially obtained cDNA library which was constructed using λgt10 as a vector. Using partial cDNA of the present invention as a probe, screening of the cDNA library (300,000 plaques) was performed using a plaque hybridization method. Procedures of screening, cloning, and sequencing were as described in Example 2 of the present invention. As a result of screening of the human brain cDNA library, positive clones containing a DNA fragment of about 3 kb were obtained. Analysis of the nucleotide sequence of part of the cDNA fragment revealed that the fragment was highly homologous to the cDNA of the present invention (Sequence ID No. 4). Example 5: Cloning of cDNA of receptors in the human LDL receptor family: A human brain cDNA library was subjected to screening using fragments of the cDNA of the present invention and fragments of the cDNA obtained in Example 4 as probes. Procedures of screening, cloning, and sequencing were as described in Example 2 of the present invention. Through screening of the human brain cDNA library, two positive clones containing cDNA fragments of about 6 kb and about 3 kb were obtained. When their nucleotide sequence was analyzed, they were identified to be a cDNA clone containing the cDNA nucleotide sequence obtained in Example 4 and a cDNA clone that overlapped therewith. Using part of these cDNAs as probes, procedures similar to those as described above were performed, to thereby obtain another cDNA clone. The DNA nucleotide sequence indicated by these cDNA clones are shown as Sequence ID No. 7. The total length of the sequence was 6,843 bp. There was an open reading frame having a size of 6,642 bp (Sequence ID No. 5). A putative amino acid sequence is shown as Sequence ID No. 6. The protein consisted of 2,214 amino acids. Comparison of the amino acid sequence with that of rabbit protein shown by Sequence ID No. 2 revealed high homology of not less than 94%. Example 6: Creation of cells that express receptors in the rabbit LDL receptor family: The cDNA as shown by Sequence ID No. 3 was ligated to phosphorylated EcoRI linker pd (CCGAATTCGG) by the use of a T4 DNA ligase, and the resultant ligated product was digested with EcoRI. Separately, a vector for expression, pBK-CMV was digested with EcoRI. The aforementioned DNA was ligated to the EcoRI-digested site of the vector using a T4 DNA ligase. Using the resultant recombinant expression vector in a calcium phosphate method [Chen, C. and H. Okayama (1987) Mol. Cell. Biol. 7, 2745-2752], host cells (CHO-1d1A7) were transformed. The resultant transformants were incubated in a Ham's F-12 selective medium supplemented with 500 µg/ml of G418, and viable cells were separated as LDL receptor analog protein-expressing cells. The cells were incubated further in the aforementioned medium. Example 7: Ligand analysis of the LDL receptor analog protein by ligand blotting: The obtained LDL receptor analog protein-expressing cells and control cells were suspended in a buffer solution containing 200 mM Tris-maleic acid (pH 6.5), 2 mM calcium chloride, 0.5 mM PMSF, 2.5 µM leupeptin, and 1% Triton X-100, to thereby solubilize the membrane protein. Solubilized membrane protein fractions were obtained through centrifugation, and electrophoresed by a 4.5-18% gradient SDS-PAGE. Thereafter, the protein was transferred onto a nitrocellulose membrane. Incubation was performed in a buffer of 50 mM Tris-HCl (pH 8.0) containing 125 I-labelled β-VLDL (10 µg/ml), 2 mM calcium chloride, and 5% bovine serum albumin. Autoradiography was performed at room temperature. A single band of about 250 kDa was detected in membrane protein fractions prepared using the present protein-expressing cells. This size coincided well with the molecular weight of 248 kDa calculated regarding the amino acid sequence (Sequence ID No. 2) deduced from the cDNA of the present invention. Although a similar band was detected for control cells, the expression level was much lower as compared with the case of the present protein-expressing cells. Since the protein coded by the cDNA of the present invention is considered to be a novel LDL receptor family receptor, it is expected that through analyses of this protein, details of lipoprotein metabolism mediated by the membrane receptor will be elucidated, and pathology of abnormal lipid metabolism which triggers onset and progress of arteriosclerosis will be clarified. Sequence ID No. 1 Length of the Sequence: 6639 Type: nucleic acid Strandedness: double Topology: linear Molecular type: cDNA to mRNA Sequence: Sequence ID No. 2 Length of the Sequence: 2213 Type: amino acid Topology: linear Molecular type: Protein Sequence: Sequence ID No. 3 Length of the Sequence: 6961 Type: nucleic acid Strandedness: double Topology: linear Molecular type: cDNA to mRNA Feature: Name/Key: sig peptide Location: 178..261 Identification method: S Name/Key: mat peptide Location: 262..6816 Identification method: S Sequence: Sequence ID No. 4 Length of the Sequence: 300 Type: nucleic acid Strandedness: double Topology: linear Molecular type: cDNA to mRNA Sequence: Sequence ID No. 5 Length of the Sequence: 6642 Type: nucleic acid Strandedness: double Topology: linear Molecular type: cDNA to mRNA Sequence: Sequence ID No. 6 Length of the Sequence: 2214 Type: amino acid Topology: linear Molecular type: Protein Sequence: Sequence ID No. 7 Length of the Sequence: 6843 Type: nucleic acid Strandedness: double Topology: linear Molecular type: cDNA to mRNA Feature: Name/Key: sig peptide Location: 81..164 Identification method: S Name/Key: mat peptide Location: 165..6722 Identification method: S Sequence:

Claims: DNA having a nucleotide sequence as shown by Sequence ID No. 1. An LDL receptor analog protein having an amino acid sequence as shown by Sequence ID No. 2 and coded by the DNA of Claim 1. DNA having a nucleotide sequence as shown by Sequence ID No. 5. An LDL receptor analog protein having an amino acid sequence as shown by Sequence ID No. 6 and coded by the DNA of Claim 3. A recombinant vector comprising DNA as shown by Sequence ID No. 1 or 5 and a replicable vector. Transformant cells which harbor the recombinant vector of Claim 5. A method for the production of an LDL receptor analog protein comprising the steps of culturing the transformants of Claim 6 and collecting the LDL receptor analog protein produced in the culture.

Inventors: ARAI KOICHI, IWASAKI AKIO, SAITO YASUSHI, YAMAZAKI HIROYUKI, ARAI, KOICHI, IWASAKI, AKIO, SAITO, YASUSHI, YAMAZAKI, HIROYUKI
Applicants: KOWA CO, KOWA COMPANY, LTD.
Application year: 1996
Main classification: C12N15
IPC codes: C07K14, C12N5, C07H21, C12N15, C12R1, C12P21